Related Experiment Video
Updated: Dec 5, 2025

A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
Published on: February 28, 2019
Systems Genetics Approaches in Mouse Models of Group A Streptococcal Necrotizing Soft-Tissue Infections
Suba Nookala1, Karthickeyan Chella Krishnan2, Santhosh Mukundan3
1Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USA. suba.nookala@und.edu.
Abstract:
Mouse models are invaluable resources for studying the pathogenesis and preclinical evaluation of therapeutics and vaccines against many human pathogens. Infections caused by group A streptococcus (GAS, Streptococcus pyogenes) are heterogeneous ranging from mild pharyngitis to severe invasive necrotizing fasciitis, a subgroup of necrotizing soft-tissue infections (NSTIs). While several strains of mice including BALB/c, C3H/HeN, CBA/J, and C57BL/10 offered significant insights, the human specificity and the interindividual variations on susceptibility or resistance to GAS infections limit their ability to mirror responses as seen in humans. In this chapter, we discuss the advanced recombinant inbred (ARI) BXD mouse model that mimics the genetic diversity as seen in humans and underpins the feasibility to map multiple genes (genetic loci) modulating GAS NSTI. GAS produces a myriad of virulence factors, including superantigens (SAg). Superantigens are potent immune toxins that activate T cells by cross-linking T cell receptors with human leukocyte antigen class-II (HLA-II) molecules expressed on antigen-presenting cells. This leads to a pro-inflammatory cytokine storm and the subsequent multiple organ damage and shock. Inbred mice are innately refractive to SAg-mediated responses. In this chapter, we discuss the versatility of the HLA-II transgenic mouse model that allowed the biological validation of known genetic associations to GAS NSTI. The combined utility of ARI-BXD and HLA-II mice as complementary approaches that offer clinically translatable insights into pathomechanisms driven by complex traits and host genetic context and novel means to evaluate the in vivo efficiency of therapies to improve outcomes of GAS NSTI are also discussed.
Insights
Advanced mouse models, including ARI-BXD and HLA-II transgenic strains, offer better insights into group A Streptococcus (GAS) necrotizing soft-tissue infections (NSTIs) by mimicking human genetic diversity and immune responses.
Area of Science:
- Immunology and Microbiology
- Genetics and Host-Pathogen Interactions
Background:
- Group A Streptococcus (GAS) infections range from mild to severe necrotizing soft-tissue infections (NSTIs).
- Existing mouse models have limitations in mirroring human specificity and interindividual variations in GAS infection susceptibility.
- GAS superantigens (SAg) trigger cytokine storms but inbred mice are refractive to these responses.
Purpose of the Study:
- To discuss advanced mouse models for studying GAS pathogenesis and evaluating therapeutics.
- To highlight the utility of ARI-BXD and HLA-II transgenic models for understanding GAS NSTI.
- To explore clinically translatable insights into complex traits and host genetic context in GAS infections.
Main Methods:
- Discussion of the advanced recombinant inbred (ARI) BXD mouse model to map genes modulating GAS NSTI.
- Exploration of the HLA-II transgenic mouse model for validating genetic associations with GAS NSTI.
- Examination of the combined utility of ARI-BXD and HLA-II mice as complementary approaches.
Main Results:
- The ARI-BXD model mimics human genetic diversity, enabling the mapping of multiple genes influencing GAS NSTI.
- The HLA-II transgenic model allows biological validation of genetic associations relevant to GAS NSTI.
- Complementary use of these models provides clinically translatable insights into GAS pathomechanisms.
Conclusions:
- Advanced mouse models like ARI-BXD and HLA-II transgenic mice are crucial for studying GAS NSTI.
- These models offer improved understanding of host genetic factors and immune responses in GAS infections.
- They provide novel means for evaluating therapeutic efficacy to improve outcomes for GAS NSTI.

